Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial

Conclusions Placebo is not non-inferior to colchicine in prevention of gout flares in the first 6 months of starting allopurinol using the ‘start-low go-slow’ strategy. After stopping colchicine, gout flares rise with no difference in the mean number of gout flares/month between groups over a 12-month period. Trial registration number ACTRN 12618001179224.
Source: Annals of the Rheumatic Diseases - Category: Rheumatology Authors: Tags: ARD Lay summaries, ARD, Crystal arthropathies Source Type: research